Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection

Severe impairment of patient‐reported outcomes in patients with chronic hepatitis C virus infection seen in real‐world practices across the world: Data from the global liver registry

“…These new treatments, direct‐acting antivirals (DAAs), are now administered as an all‐oral, interferon‐free regimen covering all HCV genotypes 1,2 . The DAA regimens have also proven to be efficacious in multiple chronic hepatitis C (CHC) subpopulations including those with cirrhosis, HIV, and with other liver diseases 1–7 …”

“…1,2 The DAA regimens have also proven to be efficacious in multiple chronic hepatitis C (CHC) subpopulations including those with cirrhosis, HIV, and with other liver diseases. [1][2][3][4][5][6][7] In addition to providing clinical benefit, DAA-based treatment for CHC has been shown to significantly improve health-related quality of life and other patient-reported outcomes (PROs) which can occur as early as 2-4 weeks after starting treatment even in the presence of advanced liver disease. [8][9][10] The economic benefit of treating all patients with DAAs, especially earlier in their disease course, is also substantial.…”